Detroit Cardiogenic Shock Initiative: Initial Results
Data presented by Dr. William O'Neill of Henry Ford Hospital System at the 66th Annual Scientific Session of the American College of Cardiology also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented collaboration between five heart hospitals in Detroit, with the goal of determining whether outcomes in cardiogenic shock can be improved by using standardized protocols including inserting Impella® early and before PCI.
Applying systematic best practices, initial results of 37 patients treated in DCSI hospitals showed an increase in cardiogenic shock survival rates from 51 percent baseline to 84 percent, with 100 percent of survivors discharged home with their native heart.
“These results validate earlier studies from the cVAD Registry that early circulatory support is critical for survival and heart recovery in cardiogenic shock,” said Dr. O’Neill. “We are proud of the positive results of our unprecedented collaboration. By sharing our best practice protocols, we remain committed to improving shock outcomes in Detroit and around the world.”
- Download the Detroit Cardiogenic Shock Initiative Treatment Algorithm
- Download Dr. O'Neill's presentation from ACC.17
- Read more about Dr. O'Neill's presentation on Abiomed's Impella Quality Assurance Program and the importance of treatment protocols to improve patient survival and heart recovery.
The mission of the IQ Assurance Program is to improve real-world outcomes in Protected PCI and cardiogenic shock patients through training, education and utilization of clinical guidelines, protocols and best practices derived from observational quality assurance data (IQ), IRB approved registry data (cVAD) and IDE approved FDA studies. The points reflected specifically in the IQ Database, as compared to the IQ Program, which includes the cVAD Registry and FDA studies, are not statistically-powered or pre-specified, and no statistical conclusions can be drawn from the observational database.
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.protectedpci.com/indications-use-safety-information/